These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38184548)

  • 1. Influence of physician networks on the implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia.
    Kurz M; Guerra-Alejos BC; Min JE; Barker B; Pauly B; Urbanoski K; Nosyk B
    Implement Sci; 2024 Jan; 19(1):3. PubMed ID: 38184548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. British Columbia's Safer Opioid Supply Policy and Opioid Outcomes.
    Nguyen HV; Mital S; Bugden S; McGinty EE
    JAMA Intern Med; 2024 Mar; 184(3):256-264. PubMed ID: 38227344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlates of opioid and benzodiazepine co-prescription among people living with HIV in British Columbia, Canada: A population-level cohort study.
    Parent S; Nolan S; Fairbairn N; Ye M; Wu A; Montaner J; Barrios R; Ti L;
    Int J Drug Policy; 2019 May; 67():52-57. PubMed ID: 30897373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey.
    Palis H; Haywood B; McDougall J; Xavier CG; Desai R; Tobias S; Burgess H; Ferguson M; Liu L; Kinniburgh B; Slaunwhite AK; Crabtree A; Buxton JA
    Harm Reduct J; 2024 Jan; 21(1):5. PubMed ID: 38184576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with 60-day adherence to "safer supply" opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency.
    Selfridge M; Card K; Kandler T; Flanagan E; Lerhe E; Heaslip A; Nguyen A; Moher M; Pauly B; Urbanoski K; Fraser C
    Int J Drug Policy; 2022 Jul; 105():103709. PubMed ID: 35525052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Postoperative Opioid Prescriptions Before and After Implementation of a Mandatory Prescription Drug Monitoring Program.
    Shenoy R; Wagner Z; Kirkegaard A; Romanelli RJ; Mudiganti S; Mariano L; Martinez M; Zanocco K; Watkins KE
    JAMA Health Forum; 2021 Oct; 2(10):e212924. PubMed ID: 35977161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study.
    Kennedy MC; Crabtree A; Nolan S; Mok WY; Cui Z; Chong M; Slaunwhite A; Ti L
    PLoS Med; 2022 Dec; 19(12):e1004123. PubMed ID: 36454732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site.
    Kolla G; Tarannum CN; Fajber K; Worku F; Norris K; Long C; Fagundes R; Rucchetto A; Hannan E; Kikot R; Klaiman M; Firestone M; Bayoumi A; Laurence G; Hayman K
    Harm Reduct J; 2024 Jan; 21(1):17. PubMed ID: 38243267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol.
    Nosyk B; Slaunwhite A; Urbanoski K; Hongdilokkul N; Palis H; Lock K; Min JE; Zhao B; Card KG; Barker B; Meilleur L; Burmeister C; Thomson E; Beck-McGreevy P; Pauly B
    BMJ Open; 2021 Jun; 11(6):e048353. PubMed ID: 34108170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Changes Have Occurred in Opioid Prescriptions and the Prescribers of Opioids Before TKA and THA? A Large National Registry Study.
    van Brug HE; Nelissen RGHH; Rosendaal FR; van Dorp ELA; Bouvy ML; Dahan A; Gademan MGJ
    Clin Orthop Relat Res; 2023 Sep; 481(9):1716-1728. PubMed ID: 37099415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving towards a continuum of safer supply options for people who use drugs: A qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada.
    Foreman-Mackey A; Pauly B; Ivsins A; Urbanoski K; Mansoor M; Bardwell G
    Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):66. PubMed ID: 36209227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid analgesic prescribing for opioid-naïve individuals prior to identification of opioid use disorder in British Columbia, Canada.
    Enns B; Krebs E; Thomson T; Dale LM; Min JE; Nosyk B
    Addiction; 2021 Dec; 116(12):3422-3432. PubMed ID: 33861882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of High-Dose Opioids Among People Living with HIV in British Columbia, Canada.
    Clark J; Fairbairn N; Nolan S; Li T; Wu A; Barrios R; Montaner J; Ti L;
    AIDS Behav; 2019 Dec; 23(12):3331-3339. PubMed ID: 31286318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study.
    Jani M; Birlie Yimer B; Sheppard T; Lunt M; Dixon WG
    PLoS Med; 2020 Oct; 17(10):e1003270. PubMed ID: 33057368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada.
    Young S; Kolla G; McCormack D; Campbell T; Leece P; Strike C; Srivastava A; Antoniou T; Bayoumi AM; Gomes T
    Int J Drug Policy; 2022 Apr; 102():103601. PubMed ID: 35124413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in opioid prescribing after implementation of mandatory registration and proactive reports within California's prescription drug monitoring program.
    Castillo-Carniglia A; González-Santa Cruz A; Cerdá M; Delcher C; Shev AB; Wintemute GJ; Henry SG
    Drug Alcohol Depend; 2021 Jan; 218():108405. PubMed ID: 33234299
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.